Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Ryan Lynch, Christina Poh, Mazyar Shadman, Brian Till, Mengyang Di, Chaitra Ujjani, Vikram Raghunathan, Stephen Smith, David Maloney, Daria Gausman, Heather Rasmussen, David Russler-Germain, Todd Fehniger, David Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2025-3591

Published: 2025

Journal Articles

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Lorenzo Iovino, Ningxin Ma, Mohamed Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani, Peter Riedell, Ajay Gopal, Leona Holmberg, Qian Wu, Sonali Smith, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2025-5483

Published: 2025

Journal Articles

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Jennifer Huang, Laura Samples, Ted Gooley, Margo Fredericks, Stephanie Louie, Grace Bishop, Christine Crider, Mehrdad Azar, Neena Kennedy, Mengyang Di, Stephen Smith, Brian Till, Ajay Gopal, Ryan Lynch, Chaitra Ujjani, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2025-2136

Published: 2025

Journal Articles

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Xiancheng Wu, Solomon Graf, Ryan Lynch, Chaitra Ujjani, Ted Gooley, Jenna Voutsinas, Heather Rasmussen, Wendy Felder, Kristi Matsumura, Andrew Cowan, Stephen Smith, Mazyar Shadman, Edus Warren, Jonathan Fromm, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5355.

https://doi.org/10.1182/blood-2025-5355

Published: 2025

Journal Articles

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Mengyang Di, Scott Huntington, Jenna Voutsinas, Qian Wu, Scott Ramsey, Jennifer Huang, Ajay Gopal, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2025-4520

Published: 2025

Journal Articles

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment

Ajay Gopal, Marek Trneny, Laurie Sehn, Julie Wu, Michael Arbushites, Oscar Bortolami, Stefano Luminari

Blood (2025) 146 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2025-1819

Published: 2025

Journal Articles

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Ryan Lynch, David Russler-Germain, Joseph Schroers-Martin, Alison Moskowitz, Reid Merryman, Azra Borogovac, Hongyan Du, Heather Rasmussen, Ranjana Advani, Ash Alizadeh, Philippe Armand, Nancy Bartlett, Alex Herrera, Matthew Mei, Sarah Rutherford, David Kurtz, Ted Gooley, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2025-5408

Published: 2025

Journal Articles

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Mengyang Di, Qian Wu, Ryan Lynch, Stephen Smith, Mazyar Shadman, Paul Martin, Brian Till, Neena Kennedy, Chaitra Ujjani, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2025-5394

Published: 2025

Journal Articles

Real-world barriers to treatment access in T-cell lymphoma

Bryce Bowler, Jenna Voutsinas, Qian Wu, Maya Krishnan, Dhruv Mistry, Grace Sun, Mazyar Shadman, Brian Till, Ryan Lynch, Vikram Raghunathan, Chaitra Ujjani, Stephen Smith, Mengyang Di, Paul Martin, Ajay Gopal, Christina Poh

Blood (2025) 146 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2025-4491

Published: 2025

Journal Articles

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

Stephen Smith, Suchitra Sundaram, Sharmila Giri, Andy Ness, Yucai Wang, Yifan Pang, Ajay Gopal, Emily Tatoian, Trenton Grossfeld, Ryan Lynch, Edus Warren, Grzegorz Nowakowski, Steven Park

Blood (2025) 146 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2025-3575

Published: 2025

Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Blood (2013) 122 (21): 85.

https://doi.org/10.1182/blood.V122.21.85.85

Published: 2013

Journal Articles

The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Lihua Pan, MD, PhD, Katherine A Guthrie, Ph.D., Brian G. Till, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD, Stephen Petersdorf, MD, William Bensinger, MD, Leona Holmberg, MD, PhD, David G. Maloney, MD, PhD, Ajay Gopal, MD

Blood (2008) 112 (11): 1143.

https://doi.org/10.1182/blood.V112.11.1143.1143

Published: 2008

Journal Articles

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Blood (2006) 108 (11): 2718.

https://doi.org/10.1182/blood.V108.11.2718.2718

Published: 2006

Journal Articles

Extracorporeal Adsorption Following Infusion of Radiolabeled Anti-CD20 Antibody Clears Unbound Radioimmunoconjugate from the Circulation and Reduces Radiation Exposure of Normal Organs in the Nonhuman Primate.

Damian J. Green, MD, Eneida R. Nemecek, MD, Nathan Hedin, BS, Anastasia Pantelias, MA, Yukang Lin, PhD, John M. Pagel, MD,PhD, Darrell R. Fisher, PhD, Don K. Hamlin, BS, D. Scott Wilbur, PhD, Ajay Gopal, MD, Rune Nilsson, PhD, Bengt E.B. Sandberg, PhD, Oliver W. Press, MD,PhD

Blood (2006) 108 (11): 2500.

https://doi.org/10.1182/blood.V108.11.2500.2500

Published: 2006

Journal Articles

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

John P. Leonard, M.D., Joseph D. Rosenblatt, M.D., Nancy L. Bartlett, M.D., Ajay Gopal, M.D., Anas Younes, M.D., David Fisher, M.D., Francine Foss, M.D., Andres Forero, M.D., Steven Bernstein, M.D., Bruce Cheson, M.D., Matthew H. Carabasi, M.D., R. Gregory Bociek, M.D., Bruce Hart, Ph.D., Michael McDonald, M.D.

Blood (2004) 104 (11): 2635.

https://doi.org/10.1182/blood.V104.11.2635.2635

Published: 2004

Journal Articles

SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma.

Andres Forero-Torres, Steven Bernstein, Ajay Gopal, Francine Foss, John Leonard, Joseph Rosenblatt, Nancy Bartlett, Anas Younes, David Fisher, Bruce Cheson, Matthew Carabasi, Gregory Bociek, Bruce Hart, Michael McDonald

Blood (2004) 104 (11): 2637.

https://doi.org/10.1182/blood.V104.11.2637.2637

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Real-world barriers to treatment access in T-cell lymphoma

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Extracorporeal Adsorption Following Infusion of Radiolabeled Anti-CD20 Antibody Clears Unbound Radioimmunoconjugate from the Circulation and Reduces Radiation Exposure of Normal Organs in the Nonhuman Primate.

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only